Article Impact Level: HIGH Data Quality: STRONG Summary of Annals of Internal Medicine, ANNALS-24-02547. https://doi.org/10.7326/ANNALS-24-02547 Dr. Dror Dicker et al.
Points
- This large-scale study analyzed data from over 44,000 U.S. adults to validate the new EASO obesity framework, which incorporates clinical comorbidities into standard BMI classifications.
- The EASO definition reclassified 18.8% of individuals from the overweight category to persons with obesity, identifying a significant population based on their associated health complications.
- While this reclassified group’s mortality risk was similar to the general normal-weight population, it was substantially lower than the risk for those with a BMI over 30.
- When explicitly compared to healthy individuals without comorbidities, this newly identified group with obesity demonstrated a significantly higher mortality risk with a hazard ratio of 1.50.
- The findings suggest that the EASO framework is a more sensitive diagnostic tool; however, further research is needed to confirm whether these patients would benefit from obesity treatments.
Summary
A recent cross-sectional and longitudinal analysis sought to validate the new European Association for the Study of Obesity (EASO) framework, which incorporates comorbidities alongside anthropometric measures. Using data from 44,030 adults aged 18 to 79 from the National Health and Nutrition Examination Survey (1999–2018), the study compared the prevalence of obesity and the risk of all-cause mortality between the new EASO definition and traditional Body Mass Index (BMI) categories. The primary objective was to determine how the new framework reclassifies individuals and to assess the mortality risk associated with this new classification.
The analysis found that the EASO framework reclassified 18.8% of individuals previously defined as overweight by BMI alone as persons with obesity (PWO). The mortality risk for this newly identified PWO group was not significantly different from that of persons with normal weight (Hazard Ratio [HR], 0.98; 95% CI, 0.87-1.10). This contrasts with the elevated risk observed in individuals with a BMI of 30 kg/m² or greater (HR, 1.19; 95% CI, 1.08-1.32). However, when compared to a healthier reference group of normal-weight individuals without significant comorbidities, the newly identified PWO demonstrated a significantly higher mortality risk (HR, 1.50; 95% CI, 1.20 to 1.88), though this risk was comparable to that of normal-weight individuals who also had comorbidities (HR, 1.74; 95% CI, 1.34 to 2.22).
Among the newly identified PWO, the most prevalent complications were hypertension (79.9%), arthritis (33.2%), diabetes (15.6%), and cardiovascular disease (10.5%). The study concludes that while the EASO framework appears to be a more sensitive diagnostic tool, identifying a high-risk population not captured by BMI alone, its clinical utility is not yet established. Further research is necessary to determine whether this newly classified group would benefit from established obesity treatments to the same extent as those traditionally identified for intervention based on BMI.
Link to the article: https://www.acpjournals.org/doi/10.7326/ANNALS-24-02547
References Dicker, D., Karpati, T., Promislow, S., & Reges, O. (2025). Implications of the european association for the study of obesity’s new framework definition of obesity: Prevalence and association with all-cause mortality. Annals of Internal Medicine, ANNALS-24-02547. https://doi.org/10.7326/ANNALS-24-02547
